ArticleBrain sciences2024

The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis.

Riccardo Bortoletto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.